Autopsy report · NCT05679492

Study on the Safety and Efficacy of Meplazumab for Injection Patients COVID-19

“Based on current epidemic situation in China, there is few Mild and Moderate COVID-19 patients.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 3

Sponsor

Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd

Sponsor type

Industry

Conditions

COVID-19

Interventions

Meplazumab foe injection; Normal saline

Participants

0

Sites

1

Countries

China

Trials that died the same way

• Ultrasonography in Norwegian Emergency Department Patients With Suspected Covid-19 Infection
  “lack of Covid-19 patients” (77% match in meaning)
• Non Verbal Communication and Dementia
  “health context of covid-19” (70% match in meaning)
• Ivermectin in Adults With Severe COVID-19.
  “Lack of severe COVID-19 cases in the place of study” (69% match in meaning)
• Efficiency of Antagonist Drugs of the Cellular Transcriptomic Signature of Influenza A Virus Infection.
  “rate of inclusion and study affected by covid-19 epidemic” (69% match in meaning)
• Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms
  “A total of 21 patients were enrolled in the study resulting in 97 total collected specimen time points. Patient recruitment was halted due to greatly decreased numbers of patient hospitalizations for Covid-19.” (69% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.